Details of the Drug Combination

General Information of Drug Combination (ID: DC5OZXL)

Drug Combination Name
Aminosalicylic Acid Pramipexole
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Aminosalicylic Acid   DMENSL5 Pramipexole   DMNMW9R
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 59.7
Bliss Independence Score: 59.7
Loewe Additivity Score: 74.31
LHighest Single Agent (HSA) Score: 74.31

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Aminosalicylic Acid
Disease Entry ICD 11 Status REF
Crohn disease DD70 Approved [2]
Inflammatory bowel disease DD72 Approved [3]
Pulmonary and extrapulmonary tuberculosis 1B10.Z Approved [3]
Pulmonary tuberculosis 1B10.Z Approved [2]
Ulcerative colitis DD71 Approved [2]
Aminosalicylic Acid Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dihydrofolate reductase (DHFR) TTYZVDJ DYR_HUMAN Modulator [5]
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Modulator [5]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Aminosalicylic Acid Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Sodium-coupled neutral amino acid transporter 3 (SLC38A3) DTKWJH3 S38A3_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Aminosalicylic Acid Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
N-acetyltransferase 2 (NAT2) DER7TA0 ARY2_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Aminosalicylic Acid Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Increases Expression [8]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Increases Expression [8]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Increases Expression [8]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [8]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Increases Expression [8]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Increases Expression [8]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Increases Expression [8]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [8]
Arylamine N-acetyltransferase 1 (NAT1) OTCCNQ3H ARY1_HUMAN Increases Acetylation [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)
Indication(s) of Pramipexole
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Approved [4]
Pramipexole Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Modulator [5]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Pramipexole Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [10]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [11]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Aminosalicylic acid FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 953).
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000 May 15;348 Pt 1:159-66.
7 Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802.
8 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
9 Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 2005 Jan 15;69(2):347-59. doi: 10.1016/j.bcp.2004.09.014. Epub 2004 Nov 24.
10 Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7.
11 OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82.